ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of March 6, 2026, ACRS stock price declined to $3.06 with 992,935 million shares trading.

ACRS has a beta of 1.33, meaning it tends to be more sensitive to market movements. ACRS has a correlation of 0.07 to the broad based SPY ETF.

ACRS has a market cap of $331.34 million. This is considered a Small Cap stock.

Last quarter Aclaris Therapeutics reported $1 million in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-719,672 and missed earnings estimates by -$.02.

In the last 3 years, ACRS traded as high as $11.12 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ACRS has outperformed the market in the last year with a return of +68.1%, while the SPY ETF gained +18.7%. In the last 3 month period, ACRS beat the market returning +4.8%, while SPY returned -1.7%. However, in the most recent 2 weeks ACRS has underperformed the stock market by returning -5.6%, while SPY returned -2.5%.

ACRS support price is $2.96 and resistance is $3.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.